Video

Diana Isaacs, PharmD: An Overview of Insulin Affordability in 2020

A look at the state of insulin affordability in 2020 and how the ongoing pandemic has impacted the situation.

The affordability of insulin is a constant topic of discussion for diabetics and their care providers. While the cost of medication was already an issue for many diabetic patients, it has been further compounded by the ongoing coronavirus disease 2019 (COVID-19) pandemic.

In the following interview, Diana Isaacs, PharmD, a clinical pharmacist and diabetes care and education specialist at the Cleveland Clinic, discusses the affordability of insulin and how the ability of patients to afford their medications has been impacted by the pandemic. A leader in her field, Isaacs offers perspective on topics from how to approach these delicate conversations with patients to the best resources for patients who may be struggling to afford their insulin.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.